Ginsenoside Rg3 attenuates the osimertinib resistance by reducing the stemness of non-small cell lung cancer cells

被引：34
作者：
Tan, Qinquan [1 ]
Lin, Shunhuan [1 ]
Zeng, Yihong [1 ]
Yao, Mantian [1 ]
Liu, Kejun [1 ]
Yuan, Haiji [1 ]
Liu, Chun [1 ]
Jiang, Guanming [1 ]
机构：
[1] Dongguan Peoples Hosp, Dept Med Oncol, Wanjiang Subdist, Guangdong, Peoples R China
来源：
ENVIRONMENTAL TOXICOLOGY | 2020年 / 35卷 / 06期
关键词：
Ginsenoside Rg3; osimertinib; non-small cell lung cancer; Hippo; TYROSINE KINASE INHIBITORS; COMBINATION; MECHANISMS; RG(3);
D O I：
10.1002/tox.22899
中图分类号：
X [环境科学、安全科学];
学科分类号：
08 ; 0830 ;
摘要：
In the present study, we found that Ginsenoside Rg3 attenuated the stemness of non-small cell lung cancer (NSCLC) cells, evident by decreasing spheroid formation ability, ALDH1 activity and stemness marker expression. Furthermore, osimertinib-resistant NSCLC cells displayed a stronger stemness than the parental cells. Ginsenoside Rg3 reduced the stemness and osimertinib resistance of osimertinib-resistant cells. RNA-sequencing revealed that Hippo signaling was shown on the top of the most upregulated pathways regulated by Ginsenoside Rg3 in NSCLC cells, and YAP/TAZ expression was suppressed by Ginsenoside Rg3. Notably, the inhibitor of Hippo signaling attenuated the effects of Ginsenoside Rg3 on the stemness of NSCLC cells. Therefore, Ginsenoside Rg3 attenuates the osimertinib resistance of NSCLC cells via suppressing the stemness, which is dependent on Hippo pathway.
引用
收藏
页码：643 / 651
页数：9
相关论文
共 20 条
  • [1] Bevacizumab in Combination with Platinum-Based Chemotherapy in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with or without Brain Metastases: A French Cohort Study (EOLE)
    Bennouna, Jaafar
    Falchero, Lionel
    Schott, Roland
    Bonnetain, Franck
    Coudert, Mathieu
    Yahia, Bechir Ben Hadj
    Chouaid, Christos
    [J]. ONCOLOGY, 2018, 94 (01) : 55 - 64
  • [2] Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
    Chabon, Jacob J.
    Simmons, Andrew D.
    Lovejoy, Alexander F.
    Esfahani, Mohammad S.
    Newman, Aaron M.
    Haringsma, Henry J.
    Kurtz, David M.
    Stehr, Henning
    Scherer, Florian
    Karlovich, Chris A.
    Harding, Thomas C.
    Durkin, Kathleen A.
    Otterson, Gregory A.
    Purcell, W. Thomas
    Camidge, D. Ross
    Goldman, Jonathan W.
    Sequist, Lecia V.
    Piotrowska, Zofia
    Wakelee, Heather A.
    Neal, Joel W.
    Alizadeh, Ash A.
    Diehn, Maximilian
    [J]. NATURE COMMUNICATIONS, 2016, 7
  • [3] 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma
    Chen, Zheng
    Wei, Xiangyu
    Shen, Lin
    Zhu, Hanshuo
    Zheng, Xuesheng
    [J]. CANCER SCIENCE, 2019, 110 (01) : 389 - 400
  • [4] Combination of ginsenoside Rg3 with docetaxel enhances the susceptibility of prostate cancer cells via inhibition of NF-κB
    Kim, Sun Mi
    Lee, So Yong
    Cho, Jin Suk
    Son, Seung Mo
    Choi, Sang Sook
    Yun, Yeo Pyo
    Yoo, Hwan Soo
    Yoon, Do Young
    Oh, Ki-Wan
    Han, Sang Bae
    Hong, Jin Tae
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2010, 631 (1-3) : 1 - 9
  • [5] Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
    Kujtan, Lara
    Subramanian, Janakiraman
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (07) : 547 - 559
  • [6] Selective toxicity of ginsenoside Rg3 on multidrug resistant cells by membrane fluidity modulation
    Kwon, Hyog-Young
    Kim, Eun-Hye
    Kim, Seung-Whan
    Kim, Su-Nam
    Park, Jong-Dae
    Rhee, Dong-Kwon
    [J]. ARCHIVES OF PHARMACAL RESEARCH, 2008, 31 (02) : 171 - 177
  • [7] Sensitization of TRAIL-Induced Cell Death by 20(S)-Ginsenoside Rg3 via CHOP-Mediated DR5 Upregulation in Human Hepatocellular Carcinoma Cells
    Lee, Ju-Yeon
    Jung, Kyung Hee
    Morgan, Michael J.
    Kang, Yi-Rae
    Lee, Hee-Seung
    Koo, Gi-Bang
    Hong, Soon-Sun
    Kwon, Sung Won
    Kim, You-Sun
    [J]. MOLECULAR CANCER THERAPEUTICS, 2013, 12 (03) : 274 - 285
  • [8] Protective autophagy decreases osimertinib cytotoxicity through regulation of stem cell-like properties in lung cancer
    Li, Li
    Wang, Yubo
    Jiao, Lin
    Lin, Caiyu
    Lu, Conghua
    Zhang, Kejun
    Hu, Chen
    Ye, Junyi
    Zhang, Dadong
    Wu, Haiyan
    Feng, Mingxia
    He, Yong
    [J]. CANCER LETTERS, 2019, 452 : 191 - 202
  • [9] Identification of differentially expressed genes and signaling pathways using bioinformatics in interstitial lung disease due to tyrosine kinase inhibitors targeting the epidermal growth factor receptor
    Lu, Yuan
    Li, Ang
    Lai, Xiaofeng
    Jiang, Jun
    Zhang, Lihong
    Zhong, Zhicheng
    Zhao, Wen
    Tang, Ping
    Zhao, Hu
    Ren, Xinling
    [J]. INVESTIGATIONAL NEW DRUGS, 2019, 37 (02) : 384 - 400
  • [10] A Novel EGFRC797 Variant Detected in a Pleural Biopsy Specimen from an Osimertinib-Treated Patient Using a Comprehensive Hybrid Capture-Based Next-Generation Sequencing Assay
    Menon, Roopika
    Mueller, Judith
    Schneider, Petra
    Lakis, Sotirios
    Thress, Kenneth
    Wolf, Juergen
    Heukamp, Lukas
    Heuckmann, Johannes M.
    Griesinger, Frank
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (09) : E105 - E107
12